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Phosphorylation is a potent mechanism regulating the activity of many intracellular enzymes. We have discovered that the product of the human 
urokinase plasminogen activator gene, pro-uPA, is phosphorylated in serine in at least wo human cell lines. Phosphorylation ccurs within the 
cell during biosynthesis, and phosphorylated intracellular p o-uPA is secreted into the medium. Of the secreted pro-uPA molecules, 20-50% are 
phosphorylated in serine, thus representing a meaningful fraction of the total biosynthetic pro-uPA. Although the sites of phosphorylation have 
not yet been determined, at least wo such sites must exist; in fact plasmin cleavage of phosphorylated single chain pro-uPA yields a two chain 
uPA in which both chains are phosphorylated. A specific function for pro-uPA phosphorylation has not yet been identified; however, it is tempting 
to speculate hat, as in many other cases, phosphorylation may affect he activity of the enzyme, its response toinhibitors or the conversion of 
pro-uPA zymogen to active two-chain uPA. This would represent an additional way of regulating extracellular proteolysis, an important pathway 
involved in both intra- and extravascular phenomena like fibrinolysis, cell migration and invasiveness. 
Plasminogen activator; Phosphosefine; Metastasis; Secretion 
1. INTRODUCTION 
Plasminogen activation (PA) is required intravascu- 
larly for digesting fibrin clots, and extravascularly for 
regulating the interactions between cell surfaces and the 
protein components of the extracellular matrix and of 
the basement membrane. The product of the PA reac- 
tion, plasmin, can degrade not only fibrin, but also pro- 
teins of the extracellular matrix and basement mem- 
brane, like proteoglycans, fibronectin, laminin and 
some collagens; in addition, it is also able to activate la- 
tent collagenases [1,2]. Two plasminogen activating en- 
zymes have been described, urokinase (uPA) and tissue 
plasminogen activator. Specific inhibitors and receptors 
for both plasminogen activators and plasminogen [3-6] 
add to the complexity of the plasminogen activation 
system. 
uPa is secreted as a 411 amino acids proenzyme [7-9] 
(pro-uPA), which can be bound to surface receptors 
(uPAR) and here be activated by a single proteolytic 
cleavage [10-12]. In the malignant A431 cell line, all 
uPAR sites are occupied in an autocrine way by uPA 
ligand produced by the same cells [13]. Similar results 
have been reported for a variety of uPA-producing 
human tumor cells [4]. This property has been sug- 
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gested to represent a distinctive advantage for migrating 
or invading cells, providing them with the tools to 
modify their connections with the surrounding cells and 
tissues, i.e. through proteolytic modification of the ex- 
tracellular matrix and basement membrane [1,4,13]. An 
important support to this view comes from the de- 
monstration of a specific localization of uPA in the 
focal contacts and in the areas of cell-to-cell contact 
[14-16]. In addition to high affinity receptors for uPA, 
cells have a large number of low affinity binding sites 
for plasminogen [6]. This leads to surface localization 
of both enzyme and substrate (uPA and plasminogen), 
and hence to the formation of surface-bound plasmin 
[16,17]. The surface location of plasmin-directed pro- 
teolysis appears to have at least two advantages: 
receptor-bound single-chain pro-uPA is activated to 
two-chain uPA at a faster rate than in solution [18] and 
surface-bound plasmin is resistant o oe-2 antiplasmin 
[6,17]. Receptor-bound activated uPA, on the other 
hand, is still accessible to inhibition by the specific 
type-l inhibitor, at lest in U937 cells [19,34] and inhibi- 
tion is followed by internalization [34-36]. 
The regulation of surface uPA, however, is only 
marginally understood. Synthesis of all components of 
the plasminogen activating system appears to undergo 
strict regulation suggesting the existence of multiple 
levels of control [20]. Other mechanisms affecting the 
interaction between uPA and its receptor have also been 
described [21,22]. 
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Pro te in  phosphory la t ion  is the best -known post-  
t rans lat iona l  mechan ism [23] regulat ing prote ins '  in- 
teract ions  and funct ions.  In an invest igat ion designed 
to unders tand  whether  phosphory la t ion  occurs in the 
uPA system, we have d iscovered that  b iosynthet ic  pro-  
uPA synthesized and secreted f rom at least two human 
cell l ines is phosphory la ted  in serine. 
2. MATERIALS  AND METHODS 
2. I. Materials 
Bovine serum albumin, aprotinin, benzamidine, phenyl-methyl- 
sulfonyl-fluoride (PMSF), sodium ortho-vanadate and plasmin were 
purchased from Sigma. Affigel used for antibody coupling and elec- 
trophoresis reagents were from BioRad. [35S]Methionine, [32p]. 
orthophosphate and 14C molecular weight protein markers were ob- 
tained from Amersham. Enlightning was from New England Nuclear. 
Human high molecular weight uPA (120 000 U/mg) and the 
monoclonal antibody 5B4, specific for the A chain of human uPA, 
have been described [12,24]. They were kind gifts of Dr M.L. Nolli 
and F. Parenti (Lepetit SPA). 
Cell culture medium (Dulbecco's modified Eagle's medium, 
DMEM), fetal bovine serum, dialysed serum, methionine-free and 
phosphate-free DMEM, glutamine, were from Gibco. 
2.2. Cell culture and labeling 
A431 human epidermoid carcinoma cells [25] were obtained from 
Ira Pastan. HT1080, human fibrosarcoma cells [15], were obtained 
from Keld Dano. Both cell lines were grown in DMEM supplemented 
with 10070 fetal bovine serum (FBS) in a 10o7o CO2 atmosphere. 
Cells were seeded at a density of 1.5 x 106 in a l0 cm plastic dish and 
grown for 24 h in 10 ml DMEM with 10070 FBS. After 24 h, the 
medium was aspirated and substituted with either methionine-free or 
phosphate-free DMEM containing 5070 dialysed FBS. After 6 h starva- 
tion, this medium was further substituted either with 2 ml methionine- 
free DMEM containing 400/LCi of [35S]methionine, or with 2 ml of 
phosphate-free, serum-free DMEM, containing 600/@Ci [32p]ortho- 
phosphate. Unless stated otherwise, cells were labeled for 18 h. 
2.3. Acid wash and cell lysates 
Labeled cells were acid-washed as previously described [13] and 
washed with phosphate buffered saline. The cell pellet was lysed by 
vortexing them for 30 s in lysis buffer (20 mM Hepes, pH 7.5, 1070 
Triton X-100, 10070 glycerol) (0.5 ml lysis buffer/10 cm plate), cen- 
trifuging the extract at 10 000 rpm at 4°C for 30 min. Both acid 
washes and cell lysates were stored frozen until use. 
2.4. Immunoprecipitation 
Media and acid washes were supplemented with one third of their 
volume of 0.2 M potassium phosphate buffer, pH 7.0, containing 2.0 
M NaCl and 0.4070 Triton X-100. The volumes used for each im- 
munoprecipitation were 0.3 ml for the 35S-labeled or 1.0 ml for the 
32p-labeled conditioned medium and 0.5-2.0 ml for the cell lysate. 
Immunoprecipitation was carried out with agarose-bound 
monoclonal antibody 5B4 as previously described using as control 
glycine-blocked agarose [13]. The immunoprecipitates were sup- 
plemented with 20/~g/ml bovine serum albumin and precipitated with 
20070 trichloroacetic acid, the pellet washed with ether and acetone, 
suspended in two-fold concentrated Laemmli buffer with /3- 
mercaptoethanol, boiled for 5 rain and analysed by SDS-poly- 
acrylamide (12.507o) gel electrophoresis [26]. Similarly treated 14C- 
molecular weight markers were run alongside. 32p-gels were directly 
dried under vacuum while 35S-gels were fixed in 25070 methanol-10070 
acetic acid, embedded inEnlightning (NEN) and dried. The dried gels 
were exposed to Kodak X-OMAT X-ray films. 
2.5. Plasmin activation of pro-uPA 
The pellet resulting from the TCA precipitation of the eluted im- 
munoprecipitates was resuspended in 30/~1 of 0.1 M Hepes buffer, pH 
7.4, in the presence of adequate concentrations of previously titrated 
plasmin and incubated for 30 rain at 37°C. At the end of the incuba- 
tion, 30/A of two-fold concentrated Laemmli buffer [26] were added, 
and the sample was boiled and analysed by 12.5070 SDS-PAGE (see 
above). 
2.6. Phosphoamino acid separation 
In order to determine the nature of the phosphorylated amino acid, 
the medium of 5 32p-labeled A431 cell dishes was pooled, im- 
munoprecipitated [13] and analysed by SDS-PAGE as described 
above. The 47 kDa pro-uPA band was cut out and boiled in 1 ml of 
1°70 SDS for 15 min, homogenized and centrifuged at 4500 rpm for 15 
min. The supernatant was collected, supplemented with 5 vols of cold 
acetone, incubated at - 15°C for 30 min, centrifuged again and the 
pellet dried. The protein pellet was washed with a 1 : 1 ether-ethanol 
mixture and suspended in 1 ml of 6 N HCl. The samples were 
hydrolysed at 110°C for 90 min, diluted with water and lyophilized 
overnight. The dried samples were taken up in 20 ~l water containing 
2 mg/ml each of phosphoserine, phosphothreonine and 
phosphotyrosine, and subjected to monodimensional thin layer elec- 
trophoresis at 1000 V at 4°C on Macherey-Nagel 100/~m thin layer 
plates, in acetic acid/pyridine water (50:5:945), pH 2.5, for 1 h. 
After the run, the cellulose plates were dried, stained with ninhydrin 
and exposed to a Kodak X-OMAT X-ray film to detect 32p-amino 
acids. 
2.7. Pulse-chase xperiments 
For these xperiments, PMA-treated (50 ng/ml) A431 ceils were us- 
ed, since they produce about 10 fold more pro-uPA (27). Ceils were 
starved and labeled with 32p orthophosphate or [~SS]methionine. The 
cells were washed twice with phosphate-free, methionine-free DMEM 
and subjected to two sets of acid washes (see above). Two of each 
group of dishes were supplemented with lysis buffer as described 
above and the resulting lysates were frozen. Serum-free DMEM (2 ml) 
containing unlabeled phosphate were added to each of the remaining 
plates which were further incubated at 37°C. The cells were then acid- 
washed again and the cell pellets lysed (see above). Both cell lysate and 
incubation supernatants were immunoprecipitated and analysed by 
SDS-PAGE (see above). 
3. RESULTS 
3.1. Secreted pro -uPA is phosphorylated in serine 
Pro -uPA secreted f rom A431 cells can be biosyn-  
thet ica l ly  labeled when the cells are incubated in 
phosphate - f ree  med ium and [32P]orthophosphate 
(Fig. 1). Th is  is not  pecul iar  o f  A431 cells and can be 
observed  also with f ib rosarcoma HT1080 cells. In both  
cell l ines, metabo l i ca l ly  labeled with either 32p or  35S the 
same 47 kDa band is specif ical ly immunoprec ip i ta ted  
wi th  ant i -u -PA  monoc lona l  ant ibody.  Its migrat ion  
cor responds  to the Mr  o f  p ro -uPA secreted f rom 35S 
meth ion ine - labe led  A431 cells [13]. Thus pro -uPA 
secreted f rom at least two  tumor  human cell l ines is 
phosphory la ted .  
We next analysed whether  p ro -uPA is phospho-  
ry lated at a single or  at mul t ip le  sites. Med ia  f rom 32p_ 
labeled A431 cells were immunoprec ip i ta ted  with anti-  
uPA  ant ibodies,  the prec ip i tate t reated with p lasmin 
which,  under  contro l led  condi t ions ,  cleaves pro -uPA in 
two  f ragments  (A and B chains)  o f  about  30 and 17 kDa 
[13], and analysed by SDS-PAGE under  reduc ing con-  
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Fig. 1. The pro-uPA secreted by A431 cells is phosphorylated• Immunoprecipitation of 35S- (part A) and 32p-labeled (part B) A431 medium using 
5B4 monoclonal ntibody coupled to affigel (lane Ab). In lanes C medium was precipitated with glycine-blocked agarose. Lane M: molecular 
weight markers• 
dit ions. As shown in Fig. 2A, two bands o f  the expected 
size are labeled, indicat ing that phosphory lated residues 
are present on both the amino-  and the carboxy-  
terminal  moieties o f  p ro -uPA.  
In order to identi fy the type of  phosphory lated amino 
acid in p ro -uPA,  32p-labeled A431 medium was im- 
munoprec ip i tated,  run in an SDS-PAGE,  the band cut 
out,  eluted and subjected to acid hydrolysis and 
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Fig. 2. (A) Limited digestion of the immuno-precipitated "P-pro-uPA with plasmin. Duplicate immunoprecipitates from the labeled medium are 
treated (lanes 2, 3) or not (lanes 0, 1) with plasmin (see section 2). C, control immunoprecipitate in which labeled medium was incubated with 
glycine-blocked agarose. (B) Determination f the phosphorylated amino acid in 32p-pro-uPA. The immunoprecipitated 32Pmedium was sub- 
jected to acid hydrolysis ( ee section 2) and analysed by high voltage lectrophoresis onthin layer plates, in the presence of unlabeled phosphoamino 
acid markers. 
111 
Volume 266, number 1,2 FEBS LETTERS June 1990 
phosphoamino acid analysis. As shown in Fig. 2B, a 
radioactive spot migrates with the phosphoserine 
marker. The experiment has been repeated several times 
on different pro-u-PA preparations with essentially the 
same result. Thus pro-u-PA is phosphorylated in serine. 
Amino acid analysis of biosynthetic pro-uPA also 
showed that phosphoserine was the only phospho- 
amino acid. Considering two phosphorylation sites per 
molecule, this analysis allowed us to estimate that be- 
tween 20 and 50% of the pro-uPA molecules are 
phosphorylated ( ata not shown). 
3.2. Phosphorylation of pro-uPA occurs intracellularly 
To exclude that phosphorylation f pro-uPA occurs 
within or in contact with the culture medium, we added 
exogenous unlabeled two-chain uPA to the medium of 
A431 cells. The use of two-chain uPA allows us to 
distinguish it from the endogenous single-chain pro- 
uPA by SDS-PAGE under reducing conditions. In no 
case labeling of the exogenous two-chain uPA was 
observed (Fig. 3). A fainter band of about 30 kDa, pro- 
bably the B chain of uPA, is present in the im- 
munoprecipitates independent of the addition of 
exogenous uPA. It probably represents degradation of
biosynthetic pro-uPA, an event often observed in con- 
ditioned media. 
We then investigated whether phosphorylated pro- 
uPA could be detected within the cells. Since A431 cells 
have receptor-bound pro-uPA which can be dissociated 
by an acid wash [13], we acid-washed 32p-labeled A431 
cells and immunoprecipitated he lysate of the acid- 
washed cells. In both 35S- and 32p-labeled cells a 47 kDa 
pro-uPA band was observed, indicating that the in- 
M - -  + C 
98 . . . . . .  
68 - : : 
45- 
30- 
21-  
Fig. 3. Exogenous two-chain uPA is not phosphorylated in A431 cell 
medium, lmmunoprecipitation f the 32P-labeled medium of A431 
cells to which no (lane -) or 7.5/~g of unlabeled two-chain uPA (lane 
+ ) had been added during the labeling period. C, control im- 
munoprecipitate (see section 2); M, molecular weight markers. 
tracellular pro-uPA is also phosphorylated ( ata not 
shown, but see Fig. 4, lane 3). These data concord with 
the idea that phosphorylation f pro-uPA occurs within 
the cells, prior to secretion. 
The amount of pro-uPA produced in culture is in 
general very low even in A431 cells which are among the 
best producers and this poses a problem in the im- 
munoprecipitation of cell lysates requiring large 
numbers of cells and of radioactive phosphate. 
However, pro-uPA synthesis in A431 cells can be in- 
creased several-fold by treatment with the tumor pro- 
moter phorbol-12-myristate-13-acetate (PMA) [27]. 
PMA treated A431 cells secrete more pro-uPA than 
controls cells, but the PMA treatment does not modify 
the fraction of phosphorylated pro-uPA, nor the ratio 
of phosphorylation between the A and B chains (data 
not shown). Using PMA treatment of A431 cells all the 
results described before could be reproduced and the 
experimental protocol simplified by the higher produc- 
tion of pro-uPA. 
To prove that phosphorylation ccurs intracellularly, 
pulse-chase experiments have been carried out. PMA- 
treated A431 cells have been starved for phosphate 
overnight and labeled for 7 h with 32p, the cells were 
acid-washed to dissociate any bound pro-uPA and in- 
cubated for 16 h in fresh medium containing unlabeled 
phosphate. As shown in Fig. 4 (left panel), at the end of 
1 2 3 4 5  
2~-'~ 
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O9 
< 
" r  
n'- t r  r r  
W - r  - r  -I- l -  t r  
I:L cO t.o co 
~/~!~ ~ ~ i~/~ --200 
-92 .5  
- 69 
-46 
-30 
Fig. 4. Pulse-chase xperiment of pro-uPA phosphorylation and 
secretion in PMA-treated A431 cells. (Left) PMA-treated A431 cells 
were pulsed for 7 h with 32p orthophosphate, acid washed and chased 
with normal DMEM for 16 h. Lane 1, molecular weight markers; 2, 
immunoprecipitation from the 7 h labeling medium; 3, im- 
munoprecipitation f the 7 h labeled acid washed cells lysate; 4, im- 
munoprecipitation from the medium after 16 h of chase; 5, im- 
munoprecipitation f  the acid-washed cell lysate after 16 h chase (see 
section 2). (Right) PMA-treated A431 cells were labeled for 18 h with 
32p orthophosphate, the labeling medium substituted with normal 
DMEM and the cells chased for 3, 5, 8 and 11 h. At each time-point 
the medium was immunoprecipitated (see section 2). The lane 'pre- 
chase' shows immunoprecipitation of the medium at the end of the 18 
h labeling period. 
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the labeling period both medium and acid-washed cells 
contain phosphorylated pro-uPA (lanes 2, 3). After 16 
h chase, phosphorylated pro-uPA appears in medium 
and decreases in the cell lysate (lanes 4, 5). Thus the 
phosphorylated pro-uPA moves from the cells into the 
medium. 
A time course of the secretion was carried out" PMA- 
treated A431 cells pre-labeled with 32p for 18 h were 
acid washed and incubated into fresh serum-free and 
phosphate-free medium, and the medium analysed for 
phosphorylated pro-uPA at different ime points. As 
shown in Fig. 4 (right panel) no pro-uPA is visible after 
3 h, but the 47 kDa band appears after 5 h and increases 
its intensity thereafter. The time course of secretion is 
not appreciably slower than that of 35S-labeled PMA- 
treated A431 cells. 
In conclusion, intracellular phosphorylated pro-uPA 
moves from cells to medium and thus represents 
phosphorylation of pro-uPA during its biosynthesis 
and before secretion; however, we cannot exclude that 
part of it does not derive from the phosphorylation f 
internalized extracellular pro-uPA. 
4. DISCUSSION 
In this paper we have shown that the product of the 
human uPA gene, pro-uPA, is phosphorylated in serine 
in human tumor cell lines. Serine phosphorylation c- 
curs intracellularly, and the phosphate group is con- 
served in the secreted form of pro-uPA. The actual 
phosphorylated serine residues have not yet been iden- 
tified: however, our preliminary data show that at least 
two phosphorylation sites exist, as both the A and B 
plasmin-generated chains are phosphorylated. Between 
20 and 50% of the secreted pro-uPA molecules are 
phosphorylated representing a considerable fraction of 
the pro-uPA output of human A431 cells. The identity 
of the pro-uPA phosphorylating enzyme is at present 
not known. Sequences resembling substrates for dif- 
ferent protein kinases are present in pro-uPA. The 
chemical identification of the phosphorylated residues 
is now being pursued. 
The potential regulatory importance of phosphoryla- 
tion is not known. Phosphorylation may modify the 
general conformation of the enzyme by adding acid 
charges and hence change the mutual positions of par- 
ticular amino acid residues. In the case of pro-uPA, one 
can imagine several possibilities: (i) Phosphorylation 
may affect he charge-relay s stem of the active site; the 
substrate (plasminogen) binding region, which again 
would affect enzymatic activity; the inhibitors binding 
region, which might affect binding of two-chain uPA to 
PAI-1 or PAI-2. We have no data at the moment on this 
point. The presence of one phosphorylation site in the 
B chain (Fig. 2) is consistent with such possibilities. (ii) 
Phosphorylation f residues at or near the activation 
region might lead to a modifcation of the rate of single- 
chain to two-chain conversion. At least three cleavage 
points have been observed in pro-uPA synthesized by in 
vitro cultured cells. One or more such breaks can occur 
on the same pro-uPA molecule. The first type of 
cleavage (Lys-158) generates the active two-chain uPA 
[28,29]. The second type, at Lys-135, liberates at low Mr 
uPA or pro-uPA (the carboxy terminus) and an amino 
terminal fragment (residues 1-135). The former has all 
the enzymatic activity, the latter can bind the receptor 
with high affinity [11]. The third type (thrombin- 
catalysed) produces a non-activatable low Mr pro-uPA 
[30]. The presence of phosphorylated residues also on 
the A chain is consistent with phosphorylation 
regulating pro-uPA processing. Our data show that 
phosphorylated pro-uPA can be cleaved by plasmin, 
but more precise concentration dependence studies will 
have to be carried out. (iii) Phosphorylation f residues 
in the growth factor domain might affect he ability of 
pro-uPA to bind the receptor. The presence of a 
phosphorylated residue on the A chain is consistent 
with this possibility, as the receptor-binding domain is 
located on the A chain of uPA [11]. 
An accurate analysis of all these possibilities will re- 
quire separation of phosphorylated from nonphospho- 
rylated pro-uPA molecules. We are currently investi- 
gating this possibility. 
If the receptor has a direct role in pro-uPA phos- 
phorylation, one would assume that pro-uPA should 
associate with the receptor within the cell; however, the 
only interaction between pro-uPA and receptor to be 
described is an autocrine one following secretion of 
pro-uPA from A431 cells [13]. In addition, the little 
available information on the structure of the uPA 
receptor does not support he possibility that the recep- 
tor itself has protein kinase activity. The uPA receptor 
is a heavily glycosylated protein of 313 amino acid 
residues with little if any intracytoplasmic domain with 
no sequence homology to known protein kinases [31]. 
Thus in conclusion, binding to the uPA receptor may 
not be involved directly in pro-uPA phosphorylation. 
Protein phosphorylation is a general regulatory 
mechanism for the activity of enzymes [32]. Hormones 
and growth factors utilize intracellular and/or mem- 
brane receptors to transduce regulatory signals that 
profoundly affect cell metabolism and cell fate. 
Phosphorylation and dephosphorylation f specific 
amino acid residues in target proteins, catalyzed by 
specific protein kinases and protein phosphatases, has a 
major role in these pathways [32,33]. The activity of 
these enzymes i  often regulated by metabolic signals, 
like Ca 2÷, cyclic AMP, diacylglyceroL Therefore, a fur- 
ther alternative regulation of extracellular proteolysis 
might be achieved by regulating the state of 
phosphorylation and possibly the activity of the 
plasmin-forming enzyme. Plasmin, and hence 
plasminogen activators, are important elements in a 
variety of physiological, pathological nd therapeutical 
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cond i t ions  l ike f ibr inolysis,  cel lular migrat ion  and  in- 
vasiveness [1,2]. I f  phosphory la t ion  represents a way of  
regulat ing uPA activity, it will not  on ly  provide a novel  
mechan ism o f  regulat ion of  extracel lular proteolysis,  
but  will also open new paths in devis ing novel  types of  
drugs to contro l  as d i f ferent  disease states as th rom-  
bosis and  cancer metastasis.  
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